ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 931

Response to Canakinumab Treatment Is Maintained in Systemic Juvenile Idiopathic Arthritis Patients

N.M. Wulffraat1,2, N. Ruperto2, H.I. Brunner3, S. Oliveira2, Y. Uziel2, K. Nistala2, R. Cimaz2, M. Ferrandiz2, B. Flato2, M.L. Gamir2, I. Koné-Paut2, C. Gaillez4, K. Lheritier4, K. Abrams5, A. Martini2 and D.J. Lovell3, 1Pediatric Rheumatology, UMC Utrecht, Utrecht, Netherlands, 2PRINTO-Istituto Gaslini, Genova, Italy, 3PRCSG, Cincinnati, OH, 4Novartis Pharma AG, Basel, Switzerland, 5Novartis Pharmaceuticals Corporation, East Hanover, NJ

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Autoinflammatory Disease, canakinumab and monoclonal antibodies, IL-1, Systemic JIA

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Pediatric Rheumatology - Clinical and Therapeutic Aspects: Juvenile Idiopathic Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Canakinumab, a selective, human, anti-interleukin (IL) -1β monoclonal antibody, is approved for the treatment of systemic juvenile idiopathic arthritis (SJIA) patients (≥ 2 years old). SJIA is an IL-1β-mediated autoinflammatory disease, which is characterized by recurrent flares of active disease. Canakinumab treatment in patients with SJIA, allows for successful steroid dose reduction/discontinuation and reduces risk to experience a flare.1 We evaluated the maintenance of efficacy with continued canakinumab treatment in SJIA patients during the blinded randomized treatment withdrawal part of a large phase III trial.

Methods: Patients 2–19 yrs of age with active SJIA who had responded to open-label canakinumab treatment 4mg/kg/4wks sc, maintained a minimum adapted ACR Pediatric criteria [aACR] 30 for up to 32 weeks, and were steroid-free or had successfully reduced systemic steroids to a minimum dose, were randomized to either continue canakinumab or receive placebo until 37 flare events occurred.1 Patients were considered to have completed the study if they entered clinical remission on medication (CRM), i.e. achieved 24 consecutive weeks of clinical inactive disease (CID).2 A survival analysis of the time to worsening in  aACR level, after randomization for the canakinumab and placebo groups was performed.  Time to worsening is the time to fail to maintain at least the same level of aACR response seen at randomization. The change in the proportion in each group of those with CID was also evaluated.

Results: 100 pts were randomized to a canakinumab (n=50) or a placebo (n=50) group, of whom 26 (53%) and 27 (54%), respectively, had CID at the start of the randomization part. In the first 2 months, probability of maintaining aACR response was similar for both treatment groups. Thereafter, the probability of maintaining aACR response was greater in the canakinumab vs placebo groups. The median time to worsening in aACR level for patients in the placebo group was 141 days (95% CI: 85, 281), and could not be calculated for canakinumab as <50% of canakinumab group had a worsening in their aACR level by the end of this phase.  The median duration of exposure for the canakinumab group was 221.5 days (range: 8-617 days). There was a statistically significant relative risk reduction of 51% for the canakinumab vs placebo group to experience a worsening in aACR level (HR= 0.49; 95% CI: 0.27, 0.90; p=0.0131). CID was achieved by 31 (62.0%) vs 17 (34.0%) patients in canakinumab vs placebo at their last visit (OR= 3.4; 95% CI: 1.5, 8.0; p=0.0020) and CRM was reached by 20 (40%) canakinumab and 2 (4%) placebo patients by the end of the study.

Conclusion: A greater proportion of SJIA patients who continued canakinumab treatment maintained/improved their aACR response, achieved CID and CRM than pts who discontinued canakinumab by being switched to placebo, demonstrating maintenance of efficacy with continued canakinumab treatment over time.

References:

1. Ruperto N, et al. N Engl J Med 2012;367(25):2396–406.

2. Wallace CA, et al. J Rheumatol 2004;31(11):2290-4.


Disclosure:

N. M. Wulffraat,

Abbvie,

2,

Novartis, Pfizer,

5;

N. Ruperto,

To Gaslini Hospital: Abbott, Astrazeneca, BMS, Centocor Research & Development, Eli Lilly and Company, ,

2,

Astrazeneca, Bristol Myers and Squibb, Janssen Biologics B.V., Roche, Wyeth/Pfizer,

8;

H. I. Brunner,

Novartis, Roche, BMS, Pfizer, Biogen, Boehringer-Ingelheim, Jannsen, Astrazaneca,

5,

Novartis, Roche,

8;

S. Oliveira,

Novartis, Roche,

2;

Y. Uziel,

Novartis, ,

5, 9,

Novartis, Pfizer, Roche, Abbvie,

8;

K. Nistala,
None;

R. Cimaz,
None;

M. Ferrandiz,

Novartis Pharmaceutical Corporation,

2;

B. Flato,

Novartis Pharmaceutical Corporation,

2;

M. L. Gamir,
None;

I. Koné-Paut,

SOBI, Chugai,

2,

Pfizer, SOBI, Novartis, Abbvie, Celgene, Chugai,

5;

C. Gaillez,

Novartis Pharmaceutical Corporation,

3;

K. Lheritier,

Novartis Pharmaceutical Corporation,

3,

Novartis Pharmaceutical Corporation,

1;

K. Abrams,

Novartis Pharmaceutical Corporation,

1,

Novartis Pharmaceutical Corporation,

3;

A. Martini,

Abbot, Bristol Myers and Squibb, Francesco Angelini S.P.A, Glaxo Smith and Kine, Janssen Biotech Inc., Novartis, Pfizer Inc., Roche, Sanofi Aventis, Schwarz,

2,

Abbot, Amgen, Biogenidecm Bristol Myers Squibb, Astellas, Bohringer, Italfarmaco, Janssen, MedImmune, Novartis, NovoNordisk, Pfizer, Sanofi, Roche, Servier,

5,

Abbot, Amgen, Biogenidecm Bristol Myers Squibb, Astellas, Bohringer, Italfarmaco, Janssen, MedImmune, Novartis, NovoNordisk, Pfizer, Sanofi, Roche, Servier,

8;

D. J. Lovell,

National Institutes of Health- NIAMS ,

2,

Astra-Zeneca, Centocor, Amgen, Bristol Meyers Squibb, Abbott, Pfizer, Regeneron, Roche, Novartis, UBC, Forest Research Institute, Horizon, Johnson & Johnson,

5,

Novartis, Roche,

8.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/response-to-canakinumab-treatment-is-maintained-in-systemic-juvenile-idiopathic-arthritis-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology